Abstract
There are several ways to mobilize hematopoietic stem cells for autologous and allogeneic hematopoietic stem cell transplant by manipulating the bone marrow microenvironment. Granulocyte colony-stimulating factor (G-CSF) and chemotherapy have been commonly used to mobilize stem cells, but several new agents, such as the CXCR4 inhibitor plerixafor, inhibit stromal-stem cell interactions to improve stem cell yield. The minimum threshold for engraftment is 2 × 106 CD34+ cells/kg, but it has been shown that higher CD34+ stem cell dose, such as 5 × 106 CD34+ cells/kg, is associated with improved survival. Efforts to increase stem cell yield remain important to improve outcomes.
| Original language | English |
|---|---|
| Pages (from-to) | 519-523 |
| Number of pages | 5 |
| Journal | Best Practice and Research: Clinical Haematology |
| Volume | 23 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 2010 |
Keywords
- Allogeneic
- Autologous
- G-CSF
- GM-CSF
- Plerixafor
- Stem cell mobilization
Fingerprint
Dive into the research topics of 'Can every patient be mobilized?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver